On November 5, 2018 BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) reported that the company will present three abstracts at the upcoming Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) November 15-19 in Seattle (Press release, BioCryst Pharmaceuticals, NOV 5, 2018, View Source [SID1234530749]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Administration of a Liquid Formulation of BCX7353 Rapidly Provides Sustained Concentrations and Kallikrein Inhibition; Poster P153, Friday, November 16, 3:30 p.m. PT

Relationship of Target Concentrations with Efficacy: Results from the APeX-1 Study of BCX7353; Poster P157, Friday, November 16, 4:10 p.m. PT

Pharmacokinetics and Pharmacodynamics of BCX7353, an Oral Plasma Kallikrein Inhibitor, in Healthy Japanese Subjects, Poster P158, Friday, November 16, 4:20 p.m. PT
"The Annual Scientific Meeting of the ACAAI provides a focused opportunity for us to meet with many of the clinical and academic leaders driving continued innovation to improve HAE therapy, and we are excited to, once again, have an important scientific presence at the meeting," said Dr. William Sheridan, chief medical officer of BioCryst.